Clinical trial
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
NCT00122447 · Emory University, Other · Completed
Key facts
| NCT number | NCT00122447 |
|---|---|
| Title | Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance |
| Official title | CVD Risk and Prevention in Early Glucose Intolerance |
| Lead sponsor | Emory University, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH Daiichi Sankyo Industry National Center for Research Resources (NCRR) |
| Status | Completed |
| Study type | Interventional |
| Conditions | Impaired Glucose Tolerance, Prediabetic State |
| Intervention type | Drug |
| Interventions | Aspirin, Alpha lipoic acid, Olmesartan, Placebo |
| Enrollment | 84 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Jul 22, 2005 |
| Last update posted | Dec 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: